Holen Sie sich die Stockscreener-App
23.81
10.13%
2.19
Schlusskurs vom Vortag:
$21.62
Offen:
$22.29
24-Stunden-Volumen:
1.00M
Relative Volume:
1.97
Marktkapitalisierung:
$1.12B
Einnahmen:
$723.55M
Nettoeinkommen (Verlust:
$157.72M
KGV:
7.9367
EPS:
3
Netto-Cashflow:
$170.15M
1W Leistung:
+12.26%
1M Leistung:
+5.35%
6M Leistung:
-26.44%
1J Leistung:
-45.96%
1-Tages-Spanne:
$22.07
$24.70
1-Wochen-Bereich:
$20.70
$24.70
52-Wochen-Spanne:
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Vergleichen Sie AMPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.81 | 981.44M | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 12.1%Here's Why - MarketBeat
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Bought by XTX Topco Ltd - MarketBeat
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Interpace Biosciences Earnings Drop - AOL.com
Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... By GuruFocus - Investing.com Canada
Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock - MarketBeat
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds - Investing.com Canada
Earnings call transcript: Amphastar Q2 2025 beats EPS forecast, stock rises - Investing.com Canada
Amphastar August 2025 presentation slides: long-term growth strategy faces near-term headwinds - Investing.com Canada
Amphastar Pharmaceuticals Topped Earnings And Is Doubling Down At Home - Finimize
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% - TradingView
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures - MSN
Amphastar's Q2 2025: Unpacking Contradictions in BAQSIMI Growth, Manufacturing Capacity, and FDA Approvals - AInvest
Amphastar Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights - TipRanks
Amphastar Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar (AMPH) Q2 2025 Earnings Call Transcript - AOL.com
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Amphastar: Q2 Earnings Snapshot - San Francisco Chronicle
Amphastar Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q2 Revenue $174.4M, vs. FactSet Est of $174.0M - MarketScreener
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - ACCESS Newswire
Immunocore (IMCR) Q2 Revenue Jumps 30% - AOL.com
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year LowWhat's Next? - MarketBeat
Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday - MarketBeat
How many analysts rate Amphastar Pharmaceuticals Inc. as a “Buy”Explosive trading growth - Jammu Links News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by GSA Capital Partners LLP - MarketBeat
How volatile is Amphastar Pharmaceuticals Inc. stock compared to the marketFree Trading Psychology Coaching - Jammu Links News
Is it the right time to buy Amphastar Pharmaceuticals Inc. stockBuild a portfolio that outperforms the market - Jammu Links News
How does Amphastar Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What makes Amphastar Pharmaceuticals Inc. stock price move sharplyInvest smarter with advanced market data - Jammu Links News
What are the technical indicators suggesting about Amphastar Pharmaceuticals Inc.High-profit trading signals - Jammu Links News
What are Amphastar Pharmaceuticals Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Amphastar Pharmaceuticals Inc. stock in 2025Get daily updates on the hottest stocks - Jammu Links News
What catalysts could drive Amphastar Pharmaceuticals Inc. stock higher in 2025Achieve consistent double-digit growth - Jammu Links News
When is Amphastar Pharmaceuticals Inc. stock expected to show significant growthDouble-digit growth - Jammu Links News
Why is Amphastar Pharmaceuticals Inc. stock attracting strong analyst attentionMaster the art of timing market moves - Jammu Links News
Federated Hermes Inc. Reduces Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
How strong is Amphastar Pharmaceuticals Inc. company’s balance sheetPre Market Entry Points To Watch Now - Jammu Links News
Victory Capital Management Inc. Has $2.35 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.43%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):